menu
    • menu
    [{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Erasca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Naporafenib","moa":"Pan-RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Erasca","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Erasca"},{"orgOrder":0,"company":"Erasca","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Naporafenib","moa":"||Pan-RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Erasca \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ BofA Securities"},{"orgOrder":0,"company":"Erasca","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Naporafenib","moa":"||Pan-RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Erasca \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Erasca","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Naporafenib","moa":"||Pan-RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erasca \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ J.P. Morgan"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Naporafenib","moa":"||Pan-RAF","graph1":"Oncology","graph2":"Phase III","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Naporafenib","moa":"||Pan-RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Naporafenib","moa":"||Pan-RAF","graph1":"Oncology","graph2":"Phase III","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Erasca \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Naporafenib

    Menu

    Naporafenib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Erasca

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Erasca

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naporafenib,Trametinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Erasca Starts Phase 3 Trial for Naporafenib in Melanoma

                            Details : ERAS-254 (naporafenib) , an oral Pan-Raf inhibitor is being investigated with trametinib (MEK inhibitor) in patients with NRAS-mutant (NRASm) melanoma.

                            Product Name : ERAS-254

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 18, 2024

                            Lead Product(s) : Naporafenib,Trametinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Erasca

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Erasca

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naporafenib,Trametinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : J.P. Morgan

                            Deal Size : $184.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Erasca Announces Closing of Underwritten Offering of Common Stock and Additional Shares

                            Details : The net proceeds will be used to advance the clinical development of ERAS-254 (naporafenib), which is being evaluated in late-stage clinical trials for the treatment of RAS Q61X-mutated melanoma.

                            Product Name : ERAS-254

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 21, 2024

                            Lead Product(s) : Naporafenib,Trametinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : J.P. Morgan

                            Deal Size : $184.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Erasca

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Erasca

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naporafenib,Trametinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : BofA Securities

                            Deal Size : $45.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Erasca Announces $45 Million Oversubscribed Private Placement Financing

                            Details : Erasca will use the proceeds to fund R&D of its product candidates, including ERAS-254 (naporafenib) with trametinib for patients with RAS Q61X solid tumors, and other developmental programs.

                            Product Name : ERAS-254

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 27, 2024

                            Lead Product(s) : Naporafenib,Trametinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : BofA Securities

                            Deal Size : $45.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Erasca

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Erasca

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naporafenib,Trametinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Erasca Announces Clinical Trial Collaboration and Supply Agreements for Trametinib

                            Details : The collaboration will support the clinical development of the pan-RAF inhibitor ERAS-254 (naporafenib) in combination with trametinib for the treatment of patients with RAS Q61X solid tumors.

                            Product Name : ERAS-254

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 14, 2024

                            Lead Product(s) : Naporafenib,Trametinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Erasca

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Erasca

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naporafenib,Trametinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mut...

                            Details : LXH254 (naporafenib) is a potent and selective pan-RAF inhibitor, it is under phase 3 clinical development in combination with Mekinist (trametinib) for the treatment of NRAS-mutated metastatic melanoma .

                            Product Name : ERAS-254

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 12, 2023

                            Lead Product(s) : Naporafenib,Trametinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Erasca

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Erasca

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naporafenib,Trametinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients wit...

                            Details : ERAS-254 (naporafenib) is a potent and selective pan-RAF inhibitor, with a potential first-in-class and best-in-class profile, which is being investigated in combination with MEK inhibitor trametinib (MEKINIST®) in patients with RAS Q61X solid tumors.

                            Product Name : ERAS-254

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 29, 2023

                            Lead Product(s) : Naporafenib,Trametinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Interphex
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naporafenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Erasca

                            Deal Size : $300.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib

                            Details : LXH254 (naporafenib) is a potent and selective inhibitor of BRAF and CRAF, with a potential first-in-class and best-in-class profile. Erasca plans to focus on securing potential regulatory approval for naporafenib plus trametinib in RAS Q61X tissue agnos...

                            Product Name : LXH254

                            Product Type : Other Small Molecule

                            Upfront Cash : $300.0 million

                            September 12, 2022

                            Lead Product(s) : Naporafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Erasca

                            Deal Size : $300.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth